Company / Working Capital
Tarsus Pharmaceuticals, Inc. Working Capital History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$387.1M
FY2025
5-year range
$164.5M / $387.1M
FY2021-FY2025
Trend
+40.2%
vs FY2024
Sector context
#112 of 213
Health Care
What the data says
At $387M, Tarsus Pharmaceuticals, Inc.'s working capital ranks #112 of 213 in the Health Care sector. Working Capital has increased for 4 consecutive years, from $164M in FY2021 to $387M in FY2025.
Based on SEC 10-K filings.
$387M in FY2025 with a 5-year CAGR of +18.6%.
Improved from $219M to $387M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +22.6%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
#112 of 213 in Health CareTop 53% of 213This company $387.1M Sector average $934.6M
▼
-58.6% below sector average
Key checks
Key Insights
- Tarsus Pharmaceuticals, Inc.'s working capital has grown for 4 consecutive years.
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, working capital increased 40.2% year-over-year.
- Ranks #112 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $387.1M | +40.2% |
| FY2024 | $276.1M | +26.0% |
| FY2023 | $219.2M | +4.4% |
| FY2022 | $209.9M | +27.6% |
| FY2021 | $164.5M | -0.5% |
| FY2020 | $165.3M | +188.9% |
| FY2019 | $57.2M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026